9Meters Announces Financing Amid Biotech Rout
Insights - 9Meters (NMTR) announced a $30M raise this morning, selling 30M shares at $1/share. After this deal, fully diluted share count is approximately 297M. At a … Continue Reading
Premium: Read NowInsights
9Meter’s NM-002 Showing Early Signs of PS Reduction
Insights - 9Meters (NMTR) had their KOL call to give an update on the NM-002 program for short bowel syndrome (SBS). Yesterday, NMTR also announced that their interim Phase 3 … Continue Reading
Premium: Read Now
Expectations for MGTA-145 in Mobilizing Myeloma Patients for Transplant
Insights - Magenta presented data for their mobilizing agent MGTA-145 at the European Society for Blood and Marrow Transplantation (EBMT 2021). The data was not new, but it gave … Continue Reading
Premium: Read Now
No One is Safe: Biotech Rout Dragging Down The Quality Names
Insights - Biotech (XBI) had a rough week as investors are moving away from “risky” assets due to the expected rise in interest rates. The XBI ETF, … Continue Reading
Premium: Read Now
Novavax Approval Timeline Depends on FDA Acceptance of UK Only Data
Insights - Novavax (NVAX) had their business update call after market yesterday. The company provided some details on regulatory processes for their Covid vaccine. UK Approval Likely … Continue Reading
Premium: Read Now
Essa Lands Another Big Pharma Collaboration
Insights - Essa (EPIX) announced another collaboration for their candidate EPI-7386. The big pharma partner is Astellas and the two companies are testing Astellas/Pfizer enzalutamide (Xtandi) with EPI7386 in … Continue Reading
Premium: Read Now
Jounce JTX-8064 To Have Therapeutic Dose by 2H 2021
Insights - Jounce (JNCE) gave an update during their quarterly call this morning. There were no material changes and their Phase 1 studying ILT4 candidate JTX-8064 in solid tumors … Continue Reading
Premium: Read Now